Aeterna Zentaris Elects Ms. Carolyn Egbert as Independent Chair of the Board
May 23 2016 - 8:15PM
Business Wire
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”),
a specialty biopharmaceutical company engaged in developing and
commercializing novel treatments in oncology, endocrinology and
women’s health, today announced the separation of the positions of
Chairman of the Board and President and Chief Executive Officer.
Ms. Carolyn Egbert has been elected Chair of the Board, a
non-executive position, by the Company's Board of Directors, and
the position of Lead Director was eliminated. David A. Dodd, who
has served as Chairman, President and Chief Executive Officer since
2014, will continue to serve as President and Chief Executive
Officer of the Company and as a director. Mr. Juergen Ernst, the
former Lead Director, will remain as a director of the Company.
“Separating the roles of Chairman and President and Chief
Executive Officer is consistent with today's corporate governance
best practices, and is certainly appropriate for Aeterna Zentaris
as we continue to position the Company for long-term success,” said
Juergen Ernst, the Company’s outgoing Lead Director. “This action
will allow David to devote all of his energy and attention to the
leadership and management of the Company, including driving our
growth and profitability initiatives. All independent directors
look forward to continuing to work with David and his team to
capitalize on the tremendous opportunities that lie before us,” Mr.
Ernst concluded.
Ms. Egbert, who has served on the Company’s Board since August
2012, and as the Chair of its Nominating, Governance and
Compensation Committee since May 2014, formerly served Solvay
America, Inc. (“Solvay”) (a chemical and pharmaceutical company in
Houston, Texas) as its Vice President, Human Resources, as the
President of Solvay Management Services, as Global Head of Human
Resources for the pharmaceutical sector of Solvay and as Senior
Executive Vice President of Global Ethics and Compliance. During
her 20-year tenure with Solvay, she served as a director on the
Board of Directors of seven subsidiary companies and as Chair of
one subsidiary board. After retiring in 2010, she established a
consulting business providing expertise in corporate governance,
ethics and compliance, organizational development, executive
compensation and strategic human resources. She holds a Bachelor of
Sciences degree in Biological Sciences from George Washington
University, Washington D.C., and a Juris Doctor degree from Seattle
University, Seattle, Washington. She also was a Ph.D. candidate in
Pharmacology at both Georgetown University Medical School at
Washington, D.C. and Northwestern University Medical School at
Chicago, Illinois. She remains an active member of both the
Michigan State Bar and the District of Columbia Bar, Washington,
D.C.
Ms. Egbert was elected Chair of the Company’s Board for a term
ending with the meeting of the Board of Directors immediately
following the 2017 Annual Meeting of Shareholders, at which time
the Board shall select its Chair for the ensuing year.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women’s health. We are engaged in drug
development activities and in the promotion of products for others.
We are now conducting Phase 3 studies of two internally developed
compounds. The focus of our business development efforts is the
acquisition or license of products that are relevant to our
therapeutic areas of focus. We also intend to license out certain
commercial rights of internally developed products to licensees in
territories where such out-licensing would enable us to ensure
development, registration and launch of our product candidates. Our
goal is to become a growth-oriented specialty biopharmaceutical
company by pursuing successful development and commercialization of
our product portfolio, achieving successful commercial presence and
growth, while consistently delivering value to our shareholders,
employees and the medical providers and patients who will benefit
from our products. For more information, visit www.aezsinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160523006531/en/
Aeterna Zentaris Inc.Philip A. Theodore, 843-900-3211Senior Vice
PresidentIR@aezsinc.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024